Verastem Reports $25.1M Q2 2026 Revenue with VS-7375 Enrollment Commencing

Verastem Oncology exceeded expectations with $25.1M revenue and reported the first patient dosed across three registration-directed VS-7375 Phase 2 trials. The company also secured a $75M non-dilutive royalty financing, extending its cash runway into late 2027.